BNC-1021 is under clinical development by Bonac and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to GlobalData, Phase I drugs for Idiopathic Pulmonary Fibrosis have a 67% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BNC-1021’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BNC-1021 is under development for the treatment of idiopathic pulmonary fibrosis. The drug candidate is a small interfering RNA agent that targets human transforming growth factor-beta 1 messenger RNA nucleic acid. It is administered as an aerosol. It is developed based on nucleic acid platform which creates nucleic acid molecules with high stability.
Bonac is engaged in the discovery and development of nucleic acid medicine drug substance based on nucleic acid chemistry and pharmaceutical development of RNA therapeutics (nucleic acid medicines). Its pipeline products include BNC-1021, a nucleic acid for treating Idiopathic pulmonary fibrosis; BNC-1601 targeting Uveitis and diabetic retinopathy; BNC-1251 indicated for cancer; and BNC-1602 that inhibits miR29 in fibrosis diseases. Bonac has developed Bonac Nucleic Acid (nkRNA and PnkRNA), a single-stranded nucleic acid platform and R&D system based on RNA nucleic acid synthesis technology. The company works in partnership with Sumitomo Chemical Company Ltd, FUJIFILM Corp, and Kurume University for licensing, distribution, research and development of nucleic acid drugs. Bonac is headquartered in Kurume, Fukuoka, Japan.
For a complete picture of BNC-1021’s drug-specific PTSR and LoA scores, buy the report here.